Injection with Toxoplasma gondii protein affects neuron health and survival

  1. Oscar A Mendez
  2. Emiliano Flores Machado
  3. Jing Lu
  4. Anita Koshy  Is a corresponding author
  1. University of Arizona, United States

Abstract

Toxoplasma gondii is an intracellular parasite that causes a long-term latent infection of neurons. Using a custom MATLAB-based mapping program in combination with a mouse model that allows us to permanently mark neurons injected with parasite proteins, we found that Toxoplasma-injected neurons (TINs) are heterogeneously distributed in the brain, primarily localizing to the cortex followed by the striatum. In addition, we determined that cortical TINs are commonly (>50%) excitatory neurons (FoxP2+) and that striatal TINs are often (>65%) medium spiny neurons (MSNs) (FoxP2+). By performing single neuron patch-clamping on striatal TINs and neighboring uninfected MSNs, we discovered that TINs have highly aberrant electrophysiology. As approximately 90% of TINs will die by 8 weeks post-infection, this abnormal physiology suggests that injection with Toxoplasma protein— either directly or indirectly— affects neuronal health and survival. Collectively, these data offer the first insights into which neurons interact with Toxoplasma and how these interactions alter neuron physiology in vivo.

Data availability

Data for Figures 1,2,3,5,6,7 is provided.

Article and author information

Author details

  1. Oscar A Mendez

    Neuroscience GIDP, University of Arizona, Tucson, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Emiliano Flores Machado

    Neuroscience GIDP, University of Arizona, Tucson, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Jing Lu

    College of Nursing, University of Arizona, Tucson, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Anita Koshy

    Neurology; Immunobiology, University of Arizona, Tucson, United States
    For correspondence
    akoshy@arizona.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8705-3233

Funding

National Institute of Neurological Disorders and Stroke (F99 NS108514)

  • Oscar A Mendez

National Institute of Neurological Disorders and Stroke (R25 NS076437 High School Student NeuroResearch Program (HSNRP))

  • Emiliano Flores Machado

Arizona Biomedical Research Commission (ADHS14-082991)

  • Anita Koshy

National Institute of Neurological Disorders and Stroke (R01 NS095994)

  • Anita Koshy

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Malcolm J McConville, The University of Melbourne, Australia

Ethics

Animal experimentation: All mouse studies and breeding were carried out in accordance with the Public Health Service Policy on Human Care and Use of Laboratory Animals. The protocol was approved by the University of Arizona Institutional Animal Care and Use Committee. (#A-3248-01, protocol #12-391).

Version history

  1. Received: February 18, 2021
  2. Accepted: June 9, 2021
  3. Accepted Manuscript published: June 9, 2021 (version 1)
  4. Version of Record published: July 9, 2021 (version 2)
  5. Version of Record updated: July 27, 2021 (version 3)

Copyright

© 2021, Mendez et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,896
    views
  • 238
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Oscar A Mendez
  2. Emiliano Flores Machado
  3. Jing Lu
  4. Anita Koshy
(2021)
Injection with Toxoplasma gondii protein affects neuron health and survival
eLife 10:e67681.
https://doi.org/10.7554/eLife.67681

Share this article

https://doi.org/10.7554/eLife.67681

Further reading

    1. Microbiology and Infectious Disease
    Hina Khan, Partha Paul ... Dibyendu Sarkar
    Research Article

    Survival of Mycobacterium tuberculosis within the host macrophages requires the bacterial virulence regulator PhoP, but the underlying reason remains unknown. 3′,5′-Cyclic adenosine monophosphate (cAMP) is one of the most widely used second messengers, which impacts a wide range of cellular responses in microbial pathogens including M. tuberculosis. Herein, we hypothesized that intra-bacterial cAMP level could be controlled by PhoP since this major regulator plays a key role in bacterial responses against numerous stress conditions. A transcriptomic analysis reveals that PhoP functions as a repressor of cAMP-specific phosphodiesterase (PDE) Rv0805, which hydrolyzes cAMP. In keeping with these results, we find specific recruitment of the regulator within the promoter region of rv0805 PDE, and absence of phoP or ectopic expression of rv0805 independently accounts for elevated PDE synthesis, leading to the depletion of intra-bacterial cAMP level. Thus, genetic manipulation to inactivate PhoP-rv0805-cAMP pathway decreases cAMP level, stress tolerance, and intracellular survival of the bacillus.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Natalia E Ketaren, Fred D Mast ... John D Aitchison
    Research Advance

    To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.